Brief: Propanc Biopharma Updates On Preparation Of PRP And Its Recently Completed Reverse Stock Split
15/07/2019 13:35
July 15 (Reuters) - Propanc Biopharma Inc PPCBD.PK :
* PROPANC BIOPHARMA PROVIDES UPDATE ON PREPARATION OF PRP
FOR
CLINICAL TRIAL APPLICATION SUBMISSION AND RECENTLY COMPLETED
REVERSE STOCK SPLIT
* PROPANC BIOPHARMA INC - PLANS TO SUBMIT ITS FIRST CLINICAL
TRIAL
APPLICATION IN SECOND HALF OF 2019
* PROPANC BIOPHARMA INC - PLANS TO COMMENCE FIH STUDY IN
ADVANCED
CANCER PATIENTS FOR PRP DURING FIRST HALF OF 2020
Source text for Eikon: ID:nBwc25Jjra
Further company coverage: PPCBD.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Propanc Biopharma
See all newsNASDAQ TRADE HALT HALT NEWS PENDING AT 09:29 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib
Brief: Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock - SEC Filing
Brief: Propanc Biopharma To File Cta In Australia For Phase 1B Study In 30–40 Advanced Cancer Patients